Insight Molecular Diagnostics Inc.
Nasdaq · Healthcare · In Vitro & In Vivo Diagnostic Substances · Nashville, TN
IMDX chart
What traders are saying about $IMDX
Latest postsInsight Molecular Diagnostics Inc. news
- Insight Molecular Diagnostics Inc. Estimates – NASDAQ:IMDX
TradingView ·
- iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
Yahoo Finance ·
- iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings
Yahoo Finance ·
- iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
Yahoo Finance ·
- Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript
fool.com ·
- Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing
marketbeat.com ·
- Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
Yahoo Finance ·
- Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary
app.moby.co ·
- Oncocyte Q2 Earnings Call Highlights
marketbeat.com ·
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
Yahoo Finance ·
- iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
Yahoo Finance ·
- iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication
Yahoo Finance ·
Insight Molecular Diagnostics Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $4.1M | $1.9M | $1.5M | $958,000 |
| Net income | -$50,222 | -$60,663 | -$27,781 | -$72.9M |
| Diluted EPS | $-1.65 | $-4.66 | $-3.75 | $-13.25 |
| Total assets (year end) | $25.8M | $35.1M | $74.9M | $100.1M |
| Cash and equivalents (year end) | $11.6M | $8.6M | $9.4M | $20.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Insight Molecular Diagnostics Inc.
- Ticker
- IMDX (Nasdaq)
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Nashville, TN
- Incorporated in
- CA
- Fiscal year end
- December 31
- SEC CIK
- 1642380
- Former names
- OncoCyte Corp, Oncocyte Corp
Frequently asked questions
What exchange is Insight Molecular Diagnostics Inc. listed on?
Insight Molecular Diagnostics Inc. trades on the Nasdaq under the ticker symbol IMDX.
What industry is Insight Molecular Diagnostics Inc. in?
Insight Molecular Diagnostics Inc. is classified by the SEC under "In Vitro & In Vivo Diagnostic Substances", part of the Healthcare sector on StockTweeting.
Where is Insight Molecular Diagnostics Inc. headquartered?
Insight Molecular Diagnostics Inc.'s business address on file with the SEC is in Nashville, TN.
When does Insight Molecular Diagnostics Inc.'s fiscal year end?
Insight Molecular Diagnostics Inc.'s fiscal year ends on December 31.
How much revenue did Insight Molecular Diagnostics Inc. report?
Insight Molecular Diagnostics Inc. reported $4.1M in revenue for calendar year 2025, according to its SEC filings.